# Chris Dimitropoulos

> Chris Dimitropoulos is a Series B investor at Alpha Wave Global backing Medical and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Alpha Wave Global](https://shizune.co/investors/profile/falcon-edge-capital-2)
- Location: New York, United States
- Total investments: 10
- Last investment: Jun 2026
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/chris-dimitropoulos-8b53706

Chris Dimitropoulos is a Series B investor at Alpha Wave Global in New York focused on Medical and Health Care. Managing Director

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 4 | 40% |
| Health Care | 3 | 30% |
| Biotechnology | 3 | 30% |
| Biopharma | 2 | 20% |
| Therapeutics | 2 | 20% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 40% |
| Series C | 2 | 20% |
| Series A | 1 | 10% |
| Series D | 1 | 10% |
| Venture - Series Unknown | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M | Series B | Jun 18, 2026 |  |
| HistoSonics | HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels. | $102M | Series D | Aug 15, 2024 |  |
| Attralus | Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Its proprietary peptide-based pan-amyloid targeting agents have the potential to diagnose and treat all forms and stages of systemic amyloidosis. The company is focused on targeting common pathology inall systemic amyloidosis diseases, with the goal of developing treatments for all subtypes of amyloidosis, including the majority in which there are currently no treatment options. | $56M | Series B | Feb 06, 2024 |  |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $105M | Series A | Jan 30, 2024 |  |
| HI-Bio | Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which mayallow for applications that improve clinical outcomes in a broad range of immune-mediated diseases. | $95M | Series B | Jan 04, 2024 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $45M | Series C | Nov 21, 2023 |  |
| Alto Neuroscience | Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develophighly-effective medicines for targeted populations. Alto Neuroscience aims to replace today's trial-and-error clinical approach by aligning the right Alto drug with the right patient, redefining psychiatry at a time when the world needs it most. | $25M | Series B | Jan 30, 2023 |  |
| Apnimed | Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts. | $79.7M | Series C | Dec 23, 2022 |  |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $30M | Venture - Series Unknown | Sep 07, 2022 |  |
| Apnimed | Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts. | $62.5M | Series C | May 04, 2022 |  |

10 of 10 investments shown.

## Co-investors
- [Lumira Ventures](https://shizune.co/investors/profile/lumira-ventures) — VC Fund, 4 deals together
- [Alpha Wave Global](https://shizune.co/investors/profile/alpha-wave-global) — VC Fund, 3 deals together
- [Angelini Ventures](https://shizune.co/investors/profile/angelini-ventures) — VC Fund, 2 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 2 deals together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 2 deals together
- [Lightswitch Capital](https://shizune.co/investors/profile/lightswitch-capital) — VC Fund, 2 deals together

## About Alpha Wave Global

VC Fund · New York, United States

Alpha Wave is an investment company that has three main verticals; private equity, private credit, and public markets. The objective of the private equity partnerships is to invest in best-in-class venture and growth stage companies and endeavors to be helpful, long-term partners to these exceptional founders and management teams; credit, whichincludes direct private lending to businesses looking for funding solutions; and public markets in an uncorrelated strategy.Alpha Wave has offices in New York, Miami, London, Monaco, Madrid, Abu Dhabi, Tel Aviv, Bangalore, and Sydney.

5 contacts available at Alpha Wave Global.

| Name | Title | Profile |
| --- | --- | --- |
| Chris Dimitropoulos | Managing Director | https://shizune.co/investors/profile/chris-dimitropoulos-956b |
| Mohammad MM | Testing | https://shizune.co/investors/profile/mohamed-nawaz |
| Navroz Udwadia | Co-Founder and Partner | https://shizune.co/investors/profile/navroz-d-udwadia |
| Rick Gerson | Co-Founder, Chairman & Chief Investment Officer | https://shizune.co/investors/profile/rick-gerson-c5aa |
| Ryan Khoury | Co-Founder and Partner | https://shizune.co/investors/profile/ryan-khoury |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Chris Dimitropoulos invest in?

Chris Dimitropoulos invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Chris Dimitropoulos last invest?

The most recent investment recorded for Chris Dimitropoulos closed in Jun 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co